TherapeuticsMD: Q2 Earnings Reveal Commercial Progress [Seeking Alpha]
TherapeuticsMD, Inc. (TXMD)
NASDAQ:AMEX Investor Relations:
ir.therapeuticsmd.com
Company Research
Source: Seeking Alpha
TherapeuticsMD: Q2 Earnings Reveal Commercial Progress Summary TherapeuticsMD recently released their Q2 earnings that revealed a miss on EPS and a beat on earnings. The company continues to make progress in its commercial launch for IMVEXXY and BIJUVA. The company is now preparing for ANNOVERA's full-scale launch in Q1 of 2020. I review plans for my over-sized TXMD position for the remainder of 2019 and why I haven't sold one single share. TherapeuticsMD ( reported mixed Q2 earnings 61.7% Figure 1: Q2 Financial Results ( Source: TXMD These earnings results have triggered a strong response from the market, with the share price rising from around $2.00 to about $3.00 per share in a couple of days of trading. Sadly, the stock is still down about 50% over the past twelve months despite multiple FDA approvals, product launches, non-dilutive financing, and revenue growth. I was expecting a strong move up from these developments, but the market has applied relentless selling pressure. TXMD
Show less
Read more
Impact Snapshot
Event Time:
TXMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXMD alerts
High impacting TherapeuticsMD, Inc. news events
Weekly update
A roundup of the hottest topics
TXMD
News
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD Announces Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
TXMD
Sec Filings
- 3/29/24 - Form 10-K
- 3/29/24 - Form 8-K
- TXMD's page on the SEC website